Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Eder, U. Articles by Fleischhacker, W. W. Search for Related Content PubMed Citation Articles by Eder, U. Articles by Fleischhacker, W. W. Schizophrenia Spectrum Disorders Other Neuroleptics

Association of Olanzapine-Induced Weight Gain With an Increase in Body Fat

OBJECTIVE: The goal of this study was to explore the pathophysiology of weight gain during treatment with olanzapine for schizophrenia. METHOD: The authors used a prospective, controlled, open study comparing body weight, body mass index, and related biological measures in mentally and physically healthy volunteers and olanzapine-treated patients with schizophrenia. Weight, eating behavior, leptin serum levels, body mass index, and body composition were assessed over an 8-week observation period. RESULTS: A significant increase in body weight, leptin serum levels, and percentage of body fat was seen in patients treated with olanzapine, but the drug-free comparison group did not show any significant changes. The weight gain during antipsychotic treatment with olanzapine was mainly attributable to an increase in body fat; patients’ lean body mass did not change. CONCLUSIONS: In addition to the original finding that an increase in body fat is mainly responsible for olanzapine-induced weight gain, these findings confirm results obtained in other studies showing increases in body weight and serum leptin levels during treatment with second-generation antipsychotics.

This article has been cited by other articles:

				O. Sentissi, J. Epelbaum, J.-P. Olie, and M.-F. Poirier Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review Schizophr Bull, December 28, 2007; (2007) sbm141v1. [Abstract] [Full Text] [PDF]

				G.D. Cooper, L.C. Pickavance, J.P.H. Wilding, J.A. HarroLd, J.C.G. HaLford, and A.J. Goudie Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities J Psychopharmacol, June 1, 2007; 21(4): 405 - 413. [Abstract] [PDF]

				R. S. McIntyre and J. Z. Konarski Obesity and Psychiatric Disorders: Frequently Encountered Clinical Questions Focus, October 1, 2005; 3(4): 511 - 519. [Abstract] [Full Text] [PDF]

				V. J. Fedorowicz and E. Fombonne Metabolic side effects of atypical antipsychotics in children: a literature review J Psychopharmacol, September 1, 2005; 19(5): 533 - 550. [Abstract] [PDF]

				T. W. Mattox Treatment of Unintentional Weight Loss in Patients With Cancer Nutr Clin Pract, August 1, 2005; 20(4): 400 - 410. [Abstract] [Full Text] [PDF]

				M. Ader, S. P. Kim, K. J. Catalano, V. Ionut, K. Hucking, J. M. Richey, M. Kabir, and R. N. Bergman Metabolic Dysregulation With Atypical Antipsychotics Occurs in the Absence of Underlying Disease A Placebo-Controlled Study of Olanzapine and Risperidone in Dogs Diabetes, March 1, 2005; 54(3): 862 - 871. [Abstract] [Full Text] [PDF]

				A. Martin, L. Scahill, G. M. Anderson, M. Aman, L. E. Arnold, J. McCracken, C. J. McDougle, E. Tierney, S. Chuang, B. Vitiello, et al. Weight and Leptin Changes Among Risperidone-Treated Youths With Autism: 6-Month Prospective Data Am J Psychiatry, June 1, 2004; 161(6): 1125 - 1127. [Abstract] [Full Text] [PDF]

				M. J. Fell, K. M. Marshall, J. Williams, and J. C. Neill Effects of the Atypical Antipsychotic Olanzapine on Reproductive Function and Weight Gain in Female Rats J Psychopharmacol, June 1, 2004; 18(2): 149 - 155. [Abstract] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us